The Microbiome, Malignant Fungating Wounds, and Palliative Care

Mridula Vardhan, Zia Flaminio, Sakshi Sapru, Charles P. Tilley, Mei R. Fu, Christopher Comfort, Xin Li, Deepak Saxena

Research output: Contribution to journalReview article

Abstract

Malignant fungating wounds present in 5–14% of advanced cancer patients in the United States and are a result of cancerous cells infiltrating and proliferating in the skin. Presentation of malignant fungating wounds often occurs in the last 6 months of life and therefore become symbols of impending death for patients and their families. Due to the incurable and severe nature of these wounds, patients require palliative care until death to minimize pain and suffering. Symptoms associated with these chronic wounds include malodor, pain, bleeding, necrosis, large amounts of exudate, increased microbial growth, and more. Limited research using culture-based techniques has been conducted on malignant fungating wounds and therefore no optimal approach to treating these wounds has been established. Despite limited data, associations between the cutaneous microbiome of these wounds and severity of symptoms have been made. The presence of at least one strain of obligate anaerobic bacteria is linked with severe odor and exudate. A concentration of over 105/g bacteria is linked with increased pain and exudate. Bacterial metabolites such as DMTS and putrescine are linked with components of malignant fungating wound odor and degradation of periwound skin. The few but significant associations made between the malignant fungating wound microbiome and severity of symptoms indicate that further study on this topic using 16S rRNA gene sequencing may reveal potential therapeutic targets within the microbiome to significantly improve current methods of treatment used in the palliative care approach.

Original languageEnglish (US)
Article number373
JournalFrontiers in Cellular and Infection Microbiology
Volume9
DOIs
StatePublished - Nov 1 2019

Fingerprint

Microbiota
Palliative Care
Wounds and Injuries
Exudates and Transudates
Pain
Skin
Culture Techniques
Putrescine
Anaerobic Bacteria
rRNA Genes
Psychological Stress
Necrosis
Hemorrhage
Bacteria
Therapeutics
Growth

Keywords

  • cancer
  • malignant fungating wound
  • metabolomics
  • microbiome
  • pain
  • palliative care
  • skin microbiome

ASJC Scopus subject areas

  • Microbiology
  • Immunology
  • Microbiology (medical)
  • Infectious Diseases

Cite this

The Microbiome, Malignant Fungating Wounds, and Palliative Care. / Vardhan, Mridula; Flaminio, Zia; Sapru, Sakshi; Tilley, Charles P.; Fu, Mei R.; Comfort, Christopher; Li, Xin; Saxena, Deepak.

In: Frontiers in Cellular and Infection Microbiology, Vol. 9, 373, 01.11.2019.

Research output: Contribution to journalReview article

Vardhan, Mridula ; Flaminio, Zia ; Sapru, Sakshi ; Tilley, Charles P. ; Fu, Mei R. ; Comfort, Christopher ; Li, Xin ; Saxena, Deepak. / The Microbiome, Malignant Fungating Wounds, and Palliative Care. In: Frontiers in Cellular and Infection Microbiology. 2019 ; Vol. 9.
@article{2fb192f1adbd426ba9ea0430af486e3a,
title = "The Microbiome, Malignant Fungating Wounds, and Palliative Care",
abstract = "Malignant fungating wounds present in 5–14{\%} of advanced cancer patients in the United States and are a result of cancerous cells infiltrating and proliferating in the skin. Presentation of malignant fungating wounds often occurs in the last 6 months of life and therefore become symbols of impending death for patients and their families. Due to the incurable and severe nature of these wounds, patients require palliative care until death to minimize pain and suffering. Symptoms associated with these chronic wounds include malodor, pain, bleeding, necrosis, large amounts of exudate, increased microbial growth, and more. Limited research using culture-based techniques has been conducted on malignant fungating wounds and therefore no optimal approach to treating these wounds has been established. Despite limited data, associations between the cutaneous microbiome of these wounds and severity of symptoms have been made. The presence of at least one strain of obligate anaerobic bacteria is linked with severe odor and exudate. A concentration of over 105/g bacteria is linked with increased pain and exudate. Bacterial metabolites such as DMTS and putrescine are linked with components of malignant fungating wound odor and degradation of periwound skin. The few but significant associations made between the malignant fungating wound microbiome and severity of symptoms indicate that further study on this topic using 16S rRNA gene sequencing may reveal potential therapeutic targets within the microbiome to significantly improve current methods of treatment used in the palliative care approach.",
keywords = "cancer, malignant fungating wound, metabolomics, microbiome, pain, palliative care, skin microbiome",
author = "Mridula Vardhan and Zia Flaminio and Sakshi Sapru and Tilley, {Charles P.} and Fu, {Mei R.} and Christopher Comfort and Xin Li and Deepak Saxena",
year = "2019",
month = "11",
day = "1",
doi = "10.3389/fcimb.2019.00373",
language = "English (US)",
volume = "9",
journal = "Frontiers in cellular and infection microbiology",
issn = "2235-2988",
publisher = "Frontiers Media S. A.",

}

TY - JOUR

T1 - The Microbiome, Malignant Fungating Wounds, and Palliative Care

AU - Vardhan, Mridula

AU - Flaminio, Zia

AU - Sapru, Sakshi

AU - Tilley, Charles P.

AU - Fu, Mei R.

AU - Comfort, Christopher

AU - Li, Xin

AU - Saxena, Deepak

PY - 2019/11/1

Y1 - 2019/11/1

N2 - Malignant fungating wounds present in 5–14% of advanced cancer patients in the United States and are a result of cancerous cells infiltrating and proliferating in the skin. Presentation of malignant fungating wounds often occurs in the last 6 months of life and therefore become symbols of impending death for patients and their families. Due to the incurable and severe nature of these wounds, patients require palliative care until death to minimize pain and suffering. Symptoms associated with these chronic wounds include malodor, pain, bleeding, necrosis, large amounts of exudate, increased microbial growth, and more. Limited research using culture-based techniques has been conducted on malignant fungating wounds and therefore no optimal approach to treating these wounds has been established. Despite limited data, associations between the cutaneous microbiome of these wounds and severity of symptoms have been made. The presence of at least one strain of obligate anaerobic bacteria is linked with severe odor and exudate. A concentration of over 105/g bacteria is linked with increased pain and exudate. Bacterial metabolites such as DMTS and putrescine are linked with components of malignant fungating wound odor and degradation of periwound skin. The few but significant associations made between the malignant fungating wound microbiome and severity of symptoms indicate that further study on this topic using 16S rRNA gene sequencing may reveal potential therapeutic targets within the microbiome to significantly improve current methods of treatment used in the palliative care approach.

AB - Malignant fungating wounds present in 5–14% of advanced cancer patients in the United States and are a result of cancerous cells infiltrating and proliferating in the skin. Presentation of malignant fungating wounds often occurs in the last 6 months of life and therefore become symbols of impending death for patients and their families. Due to the incurable and severe nature of these wounds, patients require palliative care until death to minimize pain and suffering. Symptoms associated with these chronic wounds include malodor, pain, bleeding, necrosis, large amounts of exudate, increased microbial growth, and more. Limited research using culture-based techniques has been conducted on malignant fungating wounds and therefore no optimal approach to treating these wounds has been established. Despite limited data, associations between the cutaneous microbiome of these wounds and severity of symptoms have been made. The presence of at least one strain of obligate anaerobic bacteria is linked with severe odor and exudate. A concentration of over 105/g bacteria is linked with increased pain and exudate. Bacterial metabolites such as DMTS and putrescine are linked with components of malignant fungating wound odor and degradation of periwound skin. The few but significant associations made between the malignant fungating wound microbiome and severity of symptoms indicate that further study on this topic using 16S rRNA gene sequencing may reveal potential therapeutic targets within the microbiome to significantly improve current methods of treatment used in the palliative care approach.

KW - cancer

KW - malignant fungating wound

KW - metabolomics

KW - microbiome

KW - pain

KW - palliative care

KW - skin microbiome

UR - http://www.scopus.com/inward/record.url?scp=85075208798&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85075208798&partnerID=8YFLogxK

U2 - 10.3389/fcimb.2019.00373

DO - 10.3389/fcimb.2019.00373

M3 - Review article

C2 - 31737576

AN - SCOPUS:85075208798

VL - 9

JO - Frontiers in cellular and infection microbiology

JF - Frontiers in cellular and infection microbiology

SN - 2235-2988

M1 - 373

ER -